Trial · NCT03207815
Results by group54
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 54
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percentage of Participants Failing Treatment for Active NonInfectious Uveitis by Week 24 | Filgotinib | 37.5 | 95% Confidence Interval 19.2 to 55.8 | percentage of participants | |
| Percentage of Participants Failing Treatment for Active NonInfectious Uveitis by Week 24 | Placebo | 67.6 | 95% Confidence Interval 50.5 to 84.8 | percentage of participants | |
| Time to Treatment Failure on or After Week 6 | Filgotinib | NA | Inter-Quartile Range 24.1 to NA | weeks | |
| Time to Treatment Failure on or After Week 6 | Placebo | 22.0 | Inter-Quartile Range 12.1 to 47.0 | weeks | |
| Change in Vitreous Haze (VH) Grade in Each Eye (NEI/SUN Criteria), From Best State Achieved Prior to Week 6 to Week 52 or End of Treatment (EOT) Visit or Early Termination (ET) | Filgotinib | Left Eye: Best State Prior to Week 6 | 0.3 | Standard Deviation 0.40 | score |
| Change in Vitreous Haze (VH) Grade in Each Eye (NEI/SUN Criteria), From Best State Achieved Prior to Week 6 to Week 52 or End of Treatment (EOT) Visit or Early Termination (ET) | Placebo | Left Eye: Best State Prior to Week 6 | 0.2 | Standard Deviation 0.33 | score |
| Change in Vitreous Haze (VH) Grade in Each Eye (NEI/SUN Criteria), From Best State Achieved Prior to Week 6 to Week 52 or End of Treatment (EOT) Visit or Early Termination (ET) | Filgotinib | Right Eye: Best State Prior to Week 6 | 0.3 | Standard Deviation 0.36 | score |
| Change in Vitreous Haze (VH) Grade in Each Eye (NEI/SUN Criteria), From Best State Achieved Prior to Week 6 to Week 52 or End of Treatment (EOT) Visit or Early Termination (ET) | Placebo | Right Eye: Best State Prior to Week 6 | 0.3 | Standard Deviation 0.45 | score |
| Change in Vitreous Haze (VH) Grade in Each Eye (NEI/SUN Criteria), From Best State Achieved Prior to Week 6 to Week 52 or End of Treatment (EOT) Visit or Early Termination (ET) | Filgotinib | Left Eye: Change From Best State at Week 52/EOT/ET | 0.1 | Standard Deviation 0.79 | score |
| Change in Vitreous Haze (VH) Grade in Each Eye (NEI/SUN Criteria), From Best State Achieved Prior to Week 6 to Week 52 or End of Treatment (EOT) Visit or Early Termination (ET) | Placebo | Left Eye: Change From Best State at Week 52/EOT/ET | 0.3 | Standard Deviation 0.75 | score |
| Change in Vitreous Haze (VH) Grade in Each Eye (NEI/SUN Criteria), From Best State Achieved Prior to Week 6 to Week 52 or End of Treatment (EOT) Visit or Early Termination (ET) | Filgotinib | Right Eye: Change From Best State at Week 52/EOT/ET | 0.1 | Standard Deviation 0.62 | score |
| Change in Vitreous Haze (VH) Grade in Each Eye (NEI/SUN Criteria), From Best State Achieved Prior to Week 6 to Week 52 or End of Treatment (EOT) Visit or Early Termination (ET) | Placebo | Right Eye: Change From Best State at Week 52/EOT/ET | 0.2 | Standard Deviation 0.66 | score |
| Change in Anterior Chamber (AC) Cell Grade in Each Eye, From Best State Achieved Prior to Week 6 to Week 52 or EOT Visit or ET | Filgotinib | Left Eye: Best State Prior to Week 6 | 0.0 | Standard Deviation 0.09 | score |
| Change in Anterior Chamber (AC) Cell Grade in Each Eye, From Best State Achieved Prior to Week 6 to Week 52 or EOT Visit or ET | Placebo | Left Eye: Best State Prior to Week 6 | 0.1 | Standard Deviation 0.19 | score |
| Change in Anterior Chamber (AC) Cell Grade in Each Eye, From Best State Achieved Prior to Week 6 to Week 52 or EOT Visit or ET | Filgotinib | Right Eye: Best State Prior to Week 6 | 0.0 | Standard Deviation 0.12 | score |
| Change in Anterior Chamber (AC) Cell Grade in Each Eye, From Best State Achieved Prior to Week 6 to Week 52 or EOT Visit or ET | Placebo | Right Eye: Best State Prior to Week 6 | 0.1 | Standard Deviation 0.25 | score |
| Change in Anterior Chamber (AC) Cell Grade in Each Eye, From Best State Achieved Prior to Week 6 to Week 52 or EOT Visit or ET | Filgotinib | Left Eye: Change From Best State at Week 52/EOT/ET | 0.2 | Standard Deviation 0.59 | score |
| Change in Anterior Chamber (AC) Cell Grade in Each Eye, From Best State Achieved Prior to Week 6 to Week 52 or EOT Visit or ET | Placebo | Left Eye: Change From Best State at Week 52/EOT/ET | 0.6 | Standard Deviation 0.87 | score |
| Change in Anterior Chamber (AC) Cell Grade in Each Eye, From Best State Achieved Prior to Week 6 to Week 52 or EOT Visit or ET | Filgotinib | Right Eye: Change From Best State at Week 52/EOT/ET | 0.2 | Standard Deviation 0.53 | score |
| Change in Anterior Chamber (AC) Cell Grade in Each Eye, From Best State Achieved Prior to Week 6 to Week 52 or EOT Visit or ET | Placebo | Right Eye: Change From Best State at Week 52/EOT/ET | 0.7 | Standard Deviation 1.05 | score |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03207815/results